Why Clearside BioMedical Is Monday’s Biggest Winner
Clearside BioMedical saw its shares make an incredible gain to start the week after the firm announced positive topline results from its late-stage trial.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 143
Major Biopharma Catalysts and FDA Events to Look For in March
24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of March.
With a $1 Target Price, Is MannKind at Risk of Bankruptcy?
MannKind Corp. (NASDAQ: MNKD) has been under fire from Wall Street for quite some time and is no stranger to the cold shoulder of analysts. Although, its shares did tumble in Wednesday’s session after…
Why the Celgene Damage May Be an Overreaction
Celgene watched its shares drop on Wednesday after the company announced that it received a Refusal to File letter from the FDA.
Why Valeant Pharmaceuticals Shares Are Backing Way Off
Valeant Pharmaceuticals shares tumbled after it reported its most recent quarterly results early Wednesday.
Major Biotechs Continue to See a Rising Tide of Short Interest
The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside…
Short Sellers Hike Bets in Major Pharma
The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
Could Data Breaches Break Up the Akorn Aquisition?
Akorn saw its shares crater on Tuesday after some doubts were cast on its potential acquisition by German health care group Fresnius. This isn’t the first time that Akorn has faced concerns regarding its…
Stanford’s New Cancer Immunotherapy Starting Clinical Trials Could Spur a Big Pharma Bid
Cancer immunotherapy approaches have attracted the attention of Big Pharma in the past. New technology from Stanford University probably will be no exception if Phase 1 results are positive.
Should Gilead Just Have Tried to Acquire Sangamo Rather Than a Collaboration Pact?
If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.
Meet Gilead and Sangamo’s Next Big Cancer Collaboration
Sangamo Therapeutics saw its shares make a solid gain on Thursday after the company announced that it had entered into a worldwide partnership with a subsidiary of Gilead Sciences.
Dynavax Pops With CDC Recommendation
Dynavax Technologies saw its shares make a handy gain early on Wednesday after the company announced that it received a recommendation from the CDC's Advisory Committee on Immunization Practices.
Why Tetraphase Pharmaceuticals Shares Are Popping
Tetraphase Pharmaceuticals saw its shares make a solid gain early on Wednesday after the company announced an exclusive licensing agreement in Asia.
Aimmune’s Late Stage Trial Win Not Enough for Investors
Aimmune Therapeutics shares initially made a handy gain on Tuesday after the company reported data from its late-stage peanut allergy trial.
More Health Care Catalysts to Watch For by the End of February
Here 24/7 Wall St. has included a calendar of a few of the biggest companies expecting clinical trial and FDA updates in February.